BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 25372546)

  • 1. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
    Grannis CH; Dewan VN; Wang RC
    Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral, persistent serous macular detachments with Waldenström's macroglobulinemia.
    Pilon AF; Rhee PS; Messner LV
    Optom Vis Sci; 2005 Jul; 82(7):573-8. PubMed ID: 16044069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. POSSIBLE EFFICACY OF TOPICAL DORZOLAMIDE IN THE TREATMENT OF PACLITAXEL-RELATED CYSTOID MACULAR EDEMA.
    Dwivedi R; Tiroumal S
    Retin Cases Brief Rep; 2018 Winter; 12(1):75-79. PubMed ID: 27749791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral macular detachments, venous stasis retinopathy, and retinal hemorrhages as initial presentation of multiple myeloma: a case report.
    Lam LA; Rodger DC
    Retin Cases Brief Rep; 2014; 8(4):240-4. PubMed ID: 25372517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serous macular detachment in Waldenström macroglobulinemia: a report of four cases.
    Baker PS; Garg SJ; Fineman MS; Chiang A; Alshareef RA; Belmont J; Brown GC
    Am J Ophthalmol; 2013 Mar; 155(3):448-55. PubMed ID: 23218691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
    Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal injection of ranibizumab for recovery of macular function in eyes with subfoveal polypoidal choroidal vasculopathy.
    Ogino K; Tsujikawa A; Yamashiro K; Ooto S; Oishi A; Nakata I; Miyake M; Yoshimura N
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3771-9. PubMed ID: 23661367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogammopathies and acquired vitelliform detachments: a report of four cases.
    Rusu IM; Mrejen S; Engelbert M; Gallego-Pinazo R; Ober MD; Johnson MW; Leys A; Yannuzzi LA
    Am J Ophthalmol; 2014 Mar; 157(3):648-57.e1. PubMed ID: 24321469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
    Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystoid macular edema associated with preservative-free latanoprost after uncomplicated cataract surgery: case report and review of the literature.
    Makri OE; Tsapardoni FN; Plotas P; Ifantis N; Xanthopoulou PT; Georgakopoulos CD
    BMC Res Notes; 2017 Mar; 10(1):127. PubMed ID: 28320481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection.
    Al Faran A; Mousa A; Al Shamsi H; Al Gaeed A; Ghazi NG
    Retina; 2014 Jun; 34(6):1208-15. PubMed ID: 24368308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phakic cystoid macular edema secondary to idiopathic macular telangiectasia type 1 responsive to topical anti-inflammatory agents.
    Dunn EN; Gregori NZ; Goldhardt R
    Semin Ophthalmol; 2013 Mar; 28(2):84-7. PubMed ID: 23448562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin DH; Rajkumar SV; Srkalovic G; Alsina M; Anderson KC
    Cancer; 2006 Mar; 106(6):1316-9. PubMed ID: 16470606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
    Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual acuity and microperimetric mapping of lesion area in eyes with inflammatory cystoid macular oedema.
    Munk MR; Kiss CG; Huf W; Montuoro A; Sulzbacher F; Kroh M; Larsen M; Schmidt-Erfurth U
    Acta Ophthalmol; 2014 Jun; 92(4):332-8. PubMed ID: 23802743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure.
    Malani AK; Gupta V; Rangineni R
    Acta Haematol; 2006; 116(4):255-8. PubMed ID: 17119326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
    Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
    Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.